Efficacy and Safety of Switching Prostaglandin Analog Monotherapy to Tafluprost/Timolol Fixed-Combination Therapy
Purpose. To assess the efficacy and safety of switching from prostaglandin analog (PGA) monotherapy to tafluprost/timolol fixed-combination (Taf/Tim) therapy. Subjects and Methods. Patients with primary open-angle glaucoma, normal-tension glaucoma, or ocular hypertension who had received PGA monothe...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2018-01-01
|
| Series: | Journal of Ophthalmology |
| Online Access: | http://dx.doi.org/10.1155/2018/8456764 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849683428145889280 |
|---|---|
| author | Kazuyoshi Kitamura Tatsuya Chiba Fumihiko Mabuchi Kiyotaka Ishijima Shu Omoto Fumiko Kashiwagi Takashi Godo Satoshi Kogure Teruhiko Goto Takashi Shibuya Jhoji Tanabe Shigeo Tsukahara Tadaharu Tsuchiya Toyoaki Tsumura Takaharu Tokunaga Osamu Hosaka Tetsunori Saito Kenji Kashiwagi |
| author_facet | Kazuyoshi Kitamura Tatsuya Chiba Fumihiko Mabuchi Kiyotaka Ishijima Shu Omoto Fumiko Kashiwagi Takashi Godo Satoshi Kogure Teruhiko Goto Takashi Shibuya Jhoji Tanabe Shigeo Tsukahara Tadaharu Tsuchiya Toyoaki Tsumura Takaharu Tokunaga Osamu Hosaka Tetsunori Saito Kenji Kashiwagi |
| author_sort | Kazuyoshi Kitamura |
| collection | DOAJ |
| description | Purpose. To assess the efficacy and safety of switching from prostaglandin analog (PGA) monotherapy to tafluprost/timolol fixed-combination (Taf/Tim) therapy. Subjects and Methods. Patients with primary open-angle glaucoma, normal-tension glaucoma, or ocular hypertension who had received PGA monotherapy for at least 3 months were enrolled. Patients were examined at 1, 2, and 3 months after changing therapies. Subsequently, the patients were returned to PGA monotherapy. The examined parameters included intraocular pressure (IOP) and adverse events. A questionnaire survey was conducted after the switch to Taf/Tim therapy. Results. Forty patients with a mean age of 66.5 ± 10.3 years were enrolled; 39 of these patients completed the study protocol. Switching to Taf/Tim significantly reduced the IOP from 18.2 ± 2.6 mmHg at baseline to 14.8 ± 2.5 mmHg at 1 month, 15.2 ± 2.8 mmHg at 2 months, and 14.9 ± 2.5 mmHg at 3 months (P<0.001). Switching back to the original PGA monotherapy returned the IOP values to baseline levels. Taf/Tim reduced the pulse rate insignificantly. No significant differences were observed in blood pressure, conjunctival hyperemia, or corneal adverse events. A questionnaire showed that the introduction of Taf/Tim did not significantly influence symptoms. Conclusions. Compared with PGA monotherapy, Taf/Tim fixed-combination therapy significantly reduced IOP without severe adverse events. |
| format | Article |
| id | doaj-art-d80f00209bb94635af24af918b1860d0 |
| institution | DOAJ |
| issn | 2090-004X 2090-0058 |
| language | English |
| publishDate | 2018-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of Ophthalmology |
| spelling | doaj-art-d80f00209bb94635af24af918b1860d02025-08-20T03:23:52ZengWileyJournal of Ophthalmology2090-004X2090-00582018-01-01201810.1155/2018/84567648456764Efficacy and Safety of Switching Prostaglandin Analog Monotherapy to Tafluprost/Timolol Fixed-Combination TherapyKazuyoshi Kitamura0Tatsuya Chiba1Fumihiko Mabuchi2Kiyotaka Ishijima3Shu Omoto4Fumiko Kashiwagi5Takashi Godo6Satoshi Kogure7Teruhiko Goto8Takashi Shibuya9Jhoji Tanabe10Shigeo Tsukahara11Tadaharu Tsuchiya12Toyoaki Tsumura13Takaharu Tokunaga14Osamu Hosaka15Tetsunori Saito16Kenji Kashiwagi17Department of Ophthalmology, University of Yamanashi, Chuo, Yamanashi, JapanDepartment of Ophthalmology, University of Yamanashi, Chuo, Yamanashi, JapanDepartment of Ophthalmology, University of Yamanashi, Chuo, Yamanashi, JapanDepartment of Ophthalmology, Irumagawa Hospital, Sayama, Saitama, JapanDepartment of Ophthalmology, Musashimurayama Hospital, Musashimurayama, Tokyo, JapanKashiwagi Eye Clinic, Kofu, Yamanashi, JapanGodo Eye Clinic, Iida, Nagano, JapanKogure Eye Clinic, Showa, Yamanashi, JapanGoto Eye Clinic, Kai, Yamanashi, JapanShibuya Eye Clinic, Fujikawa, Yamanashi, JapanTanabe Eye Clinic, Kai, Yamanashi, JapanDepartment of Ophthalmology, University of Yamanashi, Chuo, Yamanashi, JapanTamaho Eye Clinic, Chuo, Yamanashi, JapanDepartment of Ophthalmology, Fussa Hospital, Fussa, Tokyo, JapanMel Eye Clinic, Nishitokyo, Tokyo, JapanHosaka Eye Clinic, Chuo, Yamanashi, JapanSaito Eye Clinic, Koshu, Yamanashi, JapanDepartment of Ophthalmology, University of Yamanashi, Chuo, Yamanashi, JapanPurpose. To assess the efficacy and safety of switching from prostaglandin analog (PGA) monotherapy to tafluprost/timolol fixed-combination (Taf/Tim) therapy. Subjects and Methods. Patients with primary open-angle glaucoma, normal-tension glaucoma, or ocular hypertension who had received PGA monotherapy for at least 3 months were enrolled. Patients were examined at 1, 2, and 3 months after changing therapies. Subsequently, the patients were returned to PGA monotherapy. The examined parameters included intraocular pressure (IOP) and adverse events. A questionnaire survey was conducted after the switch to Taf/Tim therapy. Results. Forty patients with a mean age of 66.5 ± 10.3 years were enrolled; 39 of these patients completed the study protocol. Switching to Taf/Tim significantly reduced the IOP from 18.2 ± 2.6 mmHg at baseline to 14.8 ± 2.5 mmHg at 1 month, 15.2 ± 2.8 mmHg at 2 months, and 14.9 ± 2.5 mmHg at 3 months (P<0.001). Switching back to the original PGA monotherapy returned the IOP values to baseline levels. Taf/Tim reduced the pulse rate insignificantly. No significant differences were observed in blood pressure, conjunctival hyperemia, or corneal adverse events. A questionnaire showed that the introduction of Taf/Tim did not significantly influence symptoms. Conclusions. Compared with PGA monotherapy, Taf/Tim fixed-combination therapy significantly reduced IOP without severe adverse events.http://dx.doi.org/10.1155/2018/8456764 |
| spellingShingle | Kazuyoshi Kitamura Tatsuya Chiba Fumihiko Mabuchi Kiyotaka Ishijima Shu Omoto Fumiko Kashiwagi Takashi Godo Satoshi Kogure Teruhiko Goto Takashi Shibuya Jhoji Tanabe Shigeo Tsukahara Tadaharu Tsuchiya Toyoaki Tsumura Takaharu Tokunaga Osamu Hosaka Tetsunori Saito Kenji Kashiwagi Efficacy and Safety of Switching Prostaglandin Analog Monotherapy to Tafluprost/Timolol Fixed-Combination Therapy Journal of Ophthalmology |
| title | Efficacy and Safety of Switching Prostaglandin Analog Monotherapy to Tafluprost/Timolol Fixed-Combination Therapy |
| title_full | Efficacy and Safety of Switching Prostaglandin Analog Monotherapy to Tafluprost/Timolol Fixed-Combination Therapy |
| title_fullStr | Efficacy and Safety of Switching Prostaglandin Analog Monotherapy to Tafluprost/Timolol Fixed-Combination Therapy |
| title_full_unstemmed | Efficacy and Safety of Switching Prostaglandin Analog Monotherapy to Tafluprost/Timolol Fixed-Combination Therapy |
| title_short | Efficacy and Safety of Switching Prostaglandin Analog Monotherapy to Tafluprost/Timolol Fixed-Combination Therapy |
| title_sort | efficacy and safety of switching prostaglandin analog monotherapy to tafluprost timolol fixed combination therapy |
| url | http://dx.doi.org/10.1155/2018/8456764 |
| work_keys_str_mv | AT kazuyoshikitamura efficacyandsafetyofswitchingprostaglandinanalogmonotherapytotafluprosttimololfixedcombinationtherapy AT tatsuyachiba efficacyandsafetyofswitchingprostaglandinanalogmonotherapytotafluprosttimololfixedcombinationtherapy AT fumihikomabuchi efficacyandsafetyofswitchingprostaglandinanalogmonotherapytotafluprosttimololfixedcombinationtherapy AT kiyotakaishijima efficacyandsafetyofswitchingprostaglandinanalogmonotherapytotafluprosttimololfixedcombinationtherapy AT shuomoto efficacyandsafetyofswitchingprostaglandinanalogmonotherapytotafluprosttimololfixedcombinationtherapy AT fumikokashiwagi efficacyandsafetyofswitchingprostaglandinanalogmonotherapytotafluprosttimololfixedcombinationtherapy AT takashigodo efficacyandsafetyofswitchingprostaglandinanalogmonotherapytotafluprosttimololfixedcombinationtherapy AT satoshikogure efficacyandsafetyofswitchingprostaglandinanalogmonotherapytotafluprosttimololfixedcombinationtherapy AT teruhikogoto efficacyandsafetyofswitchingprostaglandinanalogmonotherapytotafluprosttimololfixedcombinationtherapy AT takashishibuya efficacyandsafetyofswitchingprostaglandinanalogmonotherapytotafluprosttimololfixedcombinationtherapy AT jhojitanabe efficacyandsafetyofswitchingprostaglandinanalogmonotherapytotafluprosttimololfixedcombinationtherapy AT shigeotsukahara efficacyandsafetyofswitchingprostaglandinanalogmonotherapytotafluprosttimololfixedcombinationtherapy AT tadaharutsuchiya efficacyandsafetyofswitchingprostaglandinanalogmonotherapytotafluprosttimololfixedcombinationtherapy AT toyoakitsumura efficacyandsafetyofswitchingprostaglandinanalogmonotherapytotafluprosttimololfixedcombinationtherapy AT takaharutokunaga efficacyandsafetyofswitchingprostaglandinanalogmonotherapytotafluprosttimololfixedcombinationtherapy AT osamuhosaka efficacyandsafetyofswitchingprostaglandinanalogmonotherapytotafluprosttimololfixedcombinationtherapy AT tetsunorisaito efficacyandsafetyofswitchingprostaglandinanalogmonotherapytotafluprosttimololfixedcombinationtherapy AT kenjikashiwagi efficacyandsafetyofswitchingprostaglandinanalogmonotherapytotafluprosttimololfixedcombinationtherapy |